(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 474.25% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.45%.
Roivant Sciences's revenue in 2026 is $7,532,000.On average, 13 Wall Street analysts forecast ROIV's revenue for 2027 to be $47,021,783,630, with the lowest ROIV revenue forecast at $10,366,057,588, and the highest ROIV revenue forecast at $141,828,123,995. On average, 11 Wall Street analysts forecast ROIV's revenue for 2028 to be $281,352,037,573, with the lowest ROIV revenue forecast at $84,237,310,009, and the highest ROIV revenue forecast at $602,959,136,771.
In 2029, ROIV is forecast to generate $1,160,050,762,090 in revenue, with the lowest revenue forecast at $910,126,998,900 and the highest revenue forecast at $1,441,756,737,940.